Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adverse events after imatinib mesylate therapy.

× No keyword cloud information.

9 in total

1. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Authors: N Widmer; L A Decosterd; C Csajka; S Leyvraz; M A Duchosal; A Rosselet; B Rochat; C B Eap; H Henry; J Biollaz; T Buclin
Journal: Br J Clin Pharmacol Date: 2006-07 Impact factor: 4.335

2. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.

Authors: Katsuya Ikuta; Yoshihiro Torimoto; Junko Jimbo; Junki Inamura; Motohiro Shindo; Kazuya Sato; Yoshihiko Tokusashi; Naoyuki Miyokawa; Yutaka Kohgo
Journal: Int J Hematol Date: 2005-11 Impact factor: 2.490

Review 3. The therapy of myelofibrosis: targeting pathogenesis.

Authors: Ruben A Mesa
Journal: Int J Hematol Date: 2002-08 Impact factor: 2.490

Review 4. Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors: Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal: Drug Saf Date: 2002 Impact factor: 5.606

5. Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery.

Authors: Shailesh V Shrikhande; Sachin S Marda; Kunal Suradkar; Supreeta Arya; Guruprasad S Shetty; Munita Bal; Parul J Shukla; Mahesh Goel; K M Mohandas
Journal: World J Surg Date: 2012-04 Impact factor: 3.352

6. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.

Authors: Hawk Kim; Heung-Moon Chang; Min-Hee Ryu; Tae-Won Kim; Hee-Jung Sohn; So-Eun Kim; Hye-Jin Kang; Sarah Park; Jung-Shin Lee; Yoon-Koo Kang
Journal: J Korean Med Sci Date: 2005-06 Impact factor: 2.153

Adverse events after imatinib mesylate therapy.

1. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

2. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.

Review 3. The therapy of myelofibrosis: targeting pathogenesis.

Review 4. Minimising the long-term adverse effects of childhood leukaemia therapy.

5. Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery.

6. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.

7. Spontaneous splenic rupture - An uncommon complication of chronic myelomonocytic leukemia.

8. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

9. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.